These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 16964263)

  • 1. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.
    Ramirez A; Heimbach A; Gründemann J; Stiller B; Hampshire D; Cid LP; Goebel I; Mubaidin AF; Wriekat AL; Roeper J; Al-Din A; Hillmer AM; Karsak M; Liss B; Woods CG; Behrens MI; Kubisch C
    Nat Genet; 2006 Oct; 38(10):1184-91. PubMed ID: 16964263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism.
    Podhajska A; Musso A; Trancikova A; Stafa K; Moser R; Sonnay S; Glauser L; Moore DJ
    PLoS One; 2012; 7(6):e39942. PubMed ID: 22768177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
    Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
    Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
    Park JS; Sue CM
    Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
    Estrada-Cuzcano A; Martin S; Chamova T; Synofzik M; Timmann D; Holemans T; Andreeva A; Reichbauer J; De Rycke R; Chang DI; van Veen S; Samuel J; Schöls L; Pöppel T; Mollerup Sørensen D; Asselbergh B; Klein C; Zuchner S; Jordanova A; Vangheluwe P; Tournev I; Schüle R
    Brain; 2017 Feb; 140(2):287-305. PubMed ID: 28137957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
    Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
    Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons.
    Matsui H; Sato F; Sato S; Koike M; Taruno Y; Saiki S; Funayama M; Ito H; Taniguchi Y; Uemura N; Toyoda A; Sakaki Y; Takeda S; Uchiyama Y; Hattori N; Takahashi R
    FEBS Lett; 2013 May; 587(9):1316-25. PubMed ID: 23499937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.
    Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D
    J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.
    Tsunemi T; Krainc D
    Hum Mol Genet; 2014 Jun; 23(11):2791-801. PubMed ID: 24334770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death.
    Ugolino J; Fang S; Kubisch C; Monteiro MJ
    Hum Mol Genet; 2011 Sep; 20(18):3565-77. PubMed ID: 21665991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.
    Pietrzak A; Badura-Stronka M; Kangas-Kontio T; Felczak P; Kozubski W; Latos-Bielenska A; Wierzba-Bobrowicz T; Florczak-Wyspianska J
    Folia Neuropathol; 2019; 57(3):285-294. PubMed ID: 31588715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
    Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/PARK9.
    Usenovic M; Krainc D
    Autophagy; 2012 Jun; 8(6):987-8. PubMed ID: 22561922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.
    Grünewald A; Arns B; Seibler P; Rakovic A; Münchau A; Ramirez A; Sue CM; Klein C
    Neurobiol Aging; 2012 Aug; 33(8):1843.e1-7. PubMed ID: 22296644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation.
    Martino D; Melzi V; Franco G; Kandasamy N; Monfrini E; Di Fonzo A
    Parkinsonism Relat Disord; 2015 Nov; 21(11):1378-80. PubMed ID: 26421390
    [No Abstract]   [Full Text] [Related]  

  • 16. α-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2.
    Kett LR; Stiller B; Bernath MM; Tasset I; Blesa J; Jackson-Lewis V; Chan RB; Zhou B; Di Paolo G; Przedborski S; Cuervo AM; Dauer WT
    J Neurosci; 2015 Apr; 35(14):5724-42. PubMed ID: 25855184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.
    Usenovic M; Knight AL; Ray A; Wong V; Brown KR; Caldwell GA; Caldwell KA; Stagljar I; Krainc D
    Hum Mol Genet; 2012 Sep; 21(17):3785-94. PubMed ID: 22645275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove.
    Dehay B; Martinez-Vicente M; Ramirez A; Perier C; Klein C; Vila M; Bezard E
    Autophagy; 2012 Sep; 8(9):1389-91. PubMed ID: 22885599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.
    Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A
    J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations.
    Erro R; Picillo M; Manara R; Pellecchia MT; Barone P
    Parkinsonism Relat Disord; 2019 Aug; 65():272-273. PubMed ID: 31151786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.